Research into probiotics and the gastrointestinal microbiota has been growing, with the aid of rapidly developing technology, over the last decade.
One strain, Lactobacillus reuteri DSM 17938, is aligned with the current literature, meets all the requirements for clinical efficacy, and is supported by over 130 human clinical trials and numerous experimental studies.
Proven strain specific modes of action:
• Colonises the entire gastrointestinal tract
• Improves gastric emptying and GI motility
• Reduces pain perception by blocking the pain receptor TRPV1
• Improves mucosal integrity and reduces GI inflammation
• Increases epithelial cell growth and migration of pathogens
• Modulates specific anti-inflammatory mediators
• Is heterofermentative; produces numerous end products (effector molecules) but is the most efficient producer of the antimicrobial substance, reuterin.
Learn more in our Lactobacillus reuteri Clinical Guide.
FREE CLINICAL GUIDE
Didn’t receive your copy of the L. Reuteri
Clinical Guide in the post?
This 30 page guide will assist you to navigate the fundamentals of L. Reuteri DSM 17938. Filled with clinical trials and study highlights, this guide is a great clinic resource.
